Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant SME-producing Serratia marcescens.
Antimicrob Agents Chemother. 2020 Jan 13;:
Authors: Biagi M, Shajee A, Vialichka A, Jurkovic M, Tan X, Wenzler E
The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME-producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem, but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3/4, 0/4, and 4/4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
PMID: 31932381 [PubMed - as supplied by publisher]